Document Detail


Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab.
MedLine Citation:
PMID:  20010453     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The purpose of this study was to report functional and morphologic retinal changes after intravitreal injections of 0.5 mg ranibizumab in patients with myopic neovascular membrane (choroidal neovascularization). METHODS: This is a case review of 11 consecutive patients with myopic choroidal neovascularization who received intravitreal injections of ranibizumab at monthly intervals. Serial changes in best-corrected visual acuity, optical coherence tomography, fluorescein angiography, and microperimetry (Nidek MP1, Nidek, Padova, Italy) are presented. RESULTS: Mean baseline best-corrected visual acuity was 59.82 + or - 17.50 Early Treatment Diabetic Retinopathy Study letters. After a follow-up of 36 weeks, mean visual acuity improved to 66.72 + or - 17.3 with a mean change of 6.91 letters. Mean baseline retinal sensitivity was 6.02 + or - 1.9 dB. After 36 weeks, mean sensitivity improved to 8.3 + or - 2.4 dB with a mean change of 2.3 dB. The fixation stability improved from 45.5% to 72.7%. All patients also had complete resolution of subretinal fluid, mean optical coherence tomography central retinal thickness was reduced from 244.64 + or - 39.3 microm to 191.36 + or - 27.3 microm at 36 weeks, and fluorescein angiography at 36 weeks showed absence of leakage in all patients. CONCLUSION: Intravitreal ranibizumab injections seemed to positively influence retinal functional status in patients with myopic choroidal neovascularization.
Authors:
Monica Varano; Massimiliano Tedeschi; Francesco Oddone; Loredana Perillo; Andrea Maria Copp?; Mariacristina Parravano
Related Documents :
12788143 - Epiretinal membrane surgery assisted by trypan blue.
17365803 - Photodynamic therapy for subfoveal and juxtafoveal choroidal neovascularization associa...
17379153 - Management of burning mouth syndrome: systematic review and management recommendations.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Retina (Philadelphia, Pa.)     Volume:  30     ISSN:  1539-2864     ISO Abbreviation:  Retina (Philadelphia, Pa.)     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-10     Completed Date:  2010-05-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309919     Medline TA:  Retina     Country:  United States    
Other Details:
Languages:  eng     Pagination:  413-7     Citation Subset:  IM    
Affiliation:
From the Fondazione G.B. Bietti, IRCCS, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal / administration & dosage*
Choroidal Neovascularization / drug therapy*,  etiology,  physiopathology*
Female
Fluorescein Angiography
Follow-Up Studies
Humans
Injections
Male
Middle Aged
Myopia, Degenerative / complications*
Perimetry
Retina / physiopathology*
Retrospective Studies
Tomography, Optical Coherence
Visual Acuity / physiology
Vitreous Body
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/ranibizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  RETINAL VESSEL ANALYZER MEASUREMENTS OF THE EFFECT OF PANRETINAL PHOTOCOAGULATION ON THE RETINAL ART...
Next Document:  Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity ...